136 related articles for article (PubMed ID: 10095173)
1. Serum levels of soluble Fas and disease activity in patients with IgA nephropathy.
Shou I; Tashiro K; Kurusu A; Kaneko S; Hayashi T; Fukui M; Shirato I; Kubota K; Tomino Y
Nephron; 1999; 81(4):387-92. PubMed ID: 10095173
[TBL] [Abstract][Full Text] [Related]
2. Tubulointerstitial changes are less important in membranoproliferative glomerulonephritis than in IgA nephropathy.
Soma J; Ootaka T; Sato H; Ito S; Saito T
Nephron; 2000 Oct; 86(2):230-1. PubMed ID: 11015015
[No Abstract] [Full Text] [Related]
3. Serum soluble interleukin-2 receptor in patients with glomerulonephritis.
Yorioka N; Hirabayashi A; Kanahara K; Takemasa A; Oda H; Joarder ZH; Yamakido M
Am J Nephrol; 1990; 10(3):181-5. PubMed ID: 2382679
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of interleukin-2 receptor and disease activity in patients with IgA nephropathy.
Tomino Y; Ozaki T; Koide H; Takahashi M; Ito K
J Clin Lab Anal; 1989; 3(6):355-9. PubMed ID: 2482345
[TBL] [Abstract][Full Text] [Related]
5. [Serum level and urinary excretion of soluble Fas (sFas) in patients with primary glomerulopathies].
Kacprzyk F
Pol Arch Med Wewn; 2002 Sep; 108(3):843-7. PubMed ID: 12600180
[TBL] [Abstract][Full Text] [Related]
6. Increase of CD23-positive cells in peripheral blood from patients with IgA nephropathy and non-IgA proliferative glomerulonephritis.
Yano N; Miyazaki M; Endoh M; Kuramoto T; Eguchi K; Yagame M; Nomoto Y; Sakai H
Nephron; 1992; 60(4):404-10. PubMed ID: 1533901
[TBL] [Abstract][Full Text] [Related]
7. Urinary levels of interleukin-8 (IL-8) and disease activity in patients with IgA nephropathy.
Huang F; Horikoshi S; Kurusu A; Shibata T; Suzuki S; Funabiki K; Shirato I; Tomino Y
J Clin Lab Anal; 2001; 15(1):30-4. PubMed ID: 11170231
[TBL] [Abstract][Full Text] [Related]
8. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Sekizuka K; Ebihara I; Koide H
Am J Nephrol; 2000; 20(5):373-9. PubMed ID: 11092994
[TBL] [Abstract][Full Text] [Related]
9. [Expression and clinical implication of platelet-derived growth factor-D and platelet-derived growth factor-beta in childhood IgA nephropathy].
Rong ZH; Wang C; Hao J; Duan HJ
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2008 May; 20(5):275-8. PubMed ID: 18471357
[TBL] [Abstract][Full Text] [Related]
10. Serum soluble interleukin 2 receptor in patients with IgA nephropathy.
Yorioka N; Hirabayashi A; Takemasa A; Kanahara K; Takahashi N; Oda H; Joarder ZH; Harada S; Yamakido M
Hiroshima J Med Sci; 1989 Dec; 38(4):169-71. PubMed ID: 2637244
[TBL] [Abstract][Full Text] [Related]
11. Measurement of plasma and urinary adrenomedullin in patients with IgA nephropathy.
Kubo A; Iwano M; Minamino N; Sato H; Nishino T; Hirata E; Akai Y; Shiiki H; Kitamura K; Kangawa K; Matsuo H; Dohi K
Nephron; 1998; 78(4):389-94. PubMed ID: 9578064
[TBL] [Abstract][Full Text] [Related]
12. Detection of activated platelets in urinary sediments by immunofluorescence using monoclonal antibody to human platelet GMP-140 in patients with IgA nephropathy.
Tomino Y; Tsushima Y; Ohmuro H; Shimizu M; Kuramoto T; Shirato I; Koide H
J Clin Lab Anal; 1993; 7(6):329-33. PubMed ID: 7506303
[TBL] [Abstract][Full Text] [Related]
13. Serum IgA/C3 ratio may predict diagnosis and prognostic grading in patients with IgA nephropathy.
Ishiguro C; Yaguchi Y; Funabiki K; Horikoshi S; Shirato I; Tomino Y
Nephron; 2002 Aug; 91(4):755-8. PubMed ID: 12138285
[TBL] [Abstract][Full Text] [Related]
14. Urinary platelet factor four (Pf4) levels in mesangial IgA glomerulonephritis and thin basement membrane disease.
Taira K; Hewitson TD; Kincaid-Smith P
Clin Nephrol; 1992 Jan; 37(1):8-13. PubMed ID: 1541068
[TBL] [Abstract][Full Text] [Related]
15. Correlation of serum levels of complement C4a desArg with pathologically estimated severity of glomerular lesions and mesangial hypercellularity scores in patients with IgA nephropathy.
Sogabe A; Uto H; Kanmura S; Nosaki T; Oyamada M; Tokunaga K; Nishida C; Fukumoto M; Oku M; Nishimoto K; Takenouchi S; Ido A; Shimada Y; Tsubouchi H
Int J Mol Med; 2013 Aug; 32(2):307-14. PubMed ID: 23708385
[TBL] [Abstract][Full Text] [Related]
16. Clinical and prognostic implications of serum uric acid levels on IgA nephropathy: a cohort study of 348 cases with a mean 5-year follow-up.
Cheng GY; Liu DW; Zhang N; Tang L; Zhao ZZ; Liu ZS
Clin Nephrol; 2013 Jul; 80(1):40-6. PubMed ID: 23391320
[TBL] [Abstract][Full Text] [Related]
17. Siblings with IgA nephropathy and diffuse proliferative glomerulonephritis (PGN) associated with identical HL-A antigens.
Miura M; Tomino Y; Yagame M; Suga T; Endoh M; Nomoto Y; Sakai H
Tokai J Exp Clin Med; 1986 Nov; 11(5):323-7. PubMed ID: 3313816
[TBL] [Abstract][Full Text] [Related]
18. Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis.
Ohtake T; Oka M; Maesato K; Mano T; Ikee R; Moriya H; Kobayashi S
Hypertens Res; 2008 Mar; 31(3):387-94. PubMed ID: 18497456
[TBL] [Abstract][Full Text] [Related]
19. Urinary levels of monocyte chemoattractant protein (MCP)-1 and disease activity in patients with IgA nephropathy.
Saitoh A; Suzuki Y; Takeda M; Kubota K; Itoh K; Tomino Y
J Clin Lab Anal; 1998; 12(1):1-5. PubMed ID: 9484662
[TBL] [Abstract][Full Text] [Related]
20. Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits complicated by immunoglobulin A nephropathy in the renal allograft.
Sawada A; Kawanishi K; Horita S; Koike J; Honda K; Ochi A; Komoda M; Tanaka Y; Unagami K; Okumi M; Shimizu T; Ishida H; Tanabe K; Nagashima Y; Nitta K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():48-52. PubMed ID: 26971743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
